Clinical trials
Breast clinical trials
Below are recruiting breast clinical trials, each written for real people, not researchers. We’re tracking 2,627 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06418204Recruiting
Cannabis use among cancer patients in community clinics
This study looks at how cancer patients use cannabis (marijuana) and cannabis products to manage symptoms during chemotherapy or immunotherapy. The goal is to learn about the benefits and risks so doctors can better guide patients.
Fairbanks, AlaskaAges 18 years+ - NCT06405295Enrolling by invitation
Intensive adjuvant therapy for BRCA-related triple-negative breast cancer
This trial tests an intensive add-on treatment for people with triple-negative breast cancer and a BRCA mutation who are at high risk of recurrence after surgery and standard treatments. The goal is to see if extra therapy helps prevent the cancer from coming back.
Beijing, Beijing MunicipalityAges 18–75 - NCT06391749Enrolling by invitation
Blood test for multiple cancers in people with symptoms
This trial tests a new blood test (SPOT-MAS) that looks for signs of multiple cancers in people who already have symptoms and are being checked with imaging. If the blood test is positive, you'll get more detailed scans or a biopsy to see if cancer is present.
Ho Chi Minh CityAges 18 years+ - NCT06393374RecruitingPhase 3
Study of a new drug combination for residual TNBC after initial treatment
This trial tests a new combination of two drugs (sacituzumab tirumotecan and pembrolizumab) compared to standard chemotherapy for people with triple-negative breast cancer that did not fully respond to initial treatment. It aims to see if this combination helps prevent cancer from coming back.
Mobile, AlabamaAges 18 years+ - NCT06380816RecruitingPhase 1/Phase 2
Study of UCB4594 for advanced cancers with HLA-G marker
This trial tests an experimental drug called UCB4594 for people with certain advanced cancers that have not responded to standard treatments. The goal is to see if the drug is safe and effective against tumors that have a specific marker called HLA-G.
LondonAges 18 years+ - NCT06375187RecruitingPhase 1
GC203 TIL for advanced solid tumors
This trial tests an experimental TIL therapy (GC203) for people with advanced solid tumors who have no more standard options. Doctors will take a piece of your tumor, make it into a personalized cell treatment, and give it back to try to fight the cancer.
ShanghaiAges 18–75 - NCT06369831RecruitingPhase 2
Imaging test for HER2 in metastatic cancer
This trial uses a special imaging scan to see if your cancer has HER2 on its surface, which could help decide if HER2-targeted treatment might work for you. It's for people with metastatic breast cancer or other solid tumors that have spread.
Innsbruck, TyrolAges 18 years+ - NCT06377852RecruitingPhase 3
CDK4/6 inhibitor dosing study for older adults with metastatic breast cancer
This study tests two targeted therapy drugs, palbociclib and ribociclib, combined with hormone therapy for people aged 60 or older with hormone receptor-positive, HER2-negative metastatic breast cancer. The goal is to see how well this treatment works and to gather information that may help improve dosing for older adults.
Chandler, ArizonaAges 60 years+ - NCT06371768Recruiting
Helping Young Cancer Survivors Manage Symptoms & Transition to Care
This study is designed to help adolescent and young adult cancer survivors manage symptoms and smoothly transition to post-treatment care. If you finished treatment for certain cancers within the past 1 to 5 years, you may be able to join.
Durham, North CarolinaAges 18–39 - NCT06351865Recruiting
Using patient feedback after digital consent
This study tests a new way of getting your consent for breast cancer surgery using digital tools. It asks for your feedback on how the consent process went.
Portsmouth, HampshireAges 18 years+ - NCT06353997RecruitingPhase 2
Neoadjuvant INBRX-106 with pembrolizumab for early-stage triple-negative breast cancer
This trial tests whether adding an experimental drug called INBRX-106 to the standard immunotherapy (pembrolizumab) and chemotherapy before surgery can improve outcomes for patients with early-stage triple-negative breast cancer. The goal is to shrink the tumor and potentially reduce the risk of the cancer coming back.
Los Angeles, CaliforniaAges 18 years+ - NCT06343831Recruiting
Measuring fat transfer results for breast reconstruction
This trial uses MRI scans to measure how well a patient's own fat stays after breast or chest wall reconstruction. The goal is to improve our understanding of fat transfer procedures.
Chicago, IllinoisAges 18 years+ - NCT04655066Recruiting
Questionnaire study for pelvic floor symptoms during cancer treatment
This study asks people with breast or gynecologic cancer who are receiving cancer treatment to complete a validated questionnaire about how their pelvic floor feels. The goal is to better understand pelvic floor function and symptoms during systemic (whole-body) cancer therapy, which may help future care.
WiesbadenAges 18 years+ - NCT06324357RecruitingPhase 1/Phase 2
Zongertinib for HER2-positive cancers that have spread
This trial tests a new pill called zongertinib, alone or with other drugs, for people with HER2-positive cancers (like breast, stomach, or colorectal cancer) that have spread and are no longer responding to standard treatments. The goal is to find the best dose and see if it can help shrink tumors or slow the disease.
Cerritos, CaliforniaAges 18 years+ - NCT05381038RecruitingPhase 1/Phase 2
Personalized azacitidine combinations for breast or stomach cancer
This Phase 1/2 trial tests different combinations that include azacitidine, chosen based on your tumor’s lab “response markers” and past drug-sensitivity screening. It aims to find safer dosing and see whether these personalized combinations can shrink solid tumors such as breast or stomach cancer.
SingaporeAges 21–99 - NCT06305962RecruitingEarly Phase 1
Radioactive drug for advanced PD-L1 positive solid tumors
This trial tests a radioactive medicine (177Lu-anti-PD-L1 sdAb) that delivers radiation to cancer cells with PD-L1 protein, which is found on some solid tumors. It is for people whose cancer has spread or come back after standard treatments.
Kingswood, New South WalesAges 18 years+ - NCT06301438Recruiting
Dalpiciclib for HR+/HER2- advanced breast cancer
This trial tests a drug called Dalpiciclib for people with a certain type of advanced breast cancer (HR-positive, HER2-negative). It aims to see if it can help stop the cancer from growing.
ShanghaiAges 18 years+ - NCT06310330Recruiting
Heart monitoring study for breast cancer patients
This study uses heart ultrasound (echocardiogram) to find early signs of heart damage from breast cancer treatment. It aims to better protect your heart during and after therapy.
TrondheimAges 18 years+ - NCT06306274Enrolling by invitationPhase 2/Phase 3
Tacrolimus cream for breast cancer-related lymphedema
This study tests if a cream called tacrolimus can help reduce swelling in the arm caused by breast cancer treatment (lymphedema). It is looking for women with mild to moderate swelling that has not yet caused severe skin changes.
OdenseAges 18 years+ - NCT06293898RecruitingPhase 1
Study of BL-M07D1 for HER2-positive solid tumors
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
Birmingham, AlabamaAges 18 years+ - NCT06258993Recruiting
Exercise program for breast cancer survivors
This study tests a new approach to help breast cancer survivors become more physically active. You will be asked to participate in a program that uses a smartphone app and wear a monitor to track activity.
Lebanon, New HampshireAges 18 years+ - NCT05322460Recruiting
Online support program for long-term breast cancer survivors
This study tests a web-based program to support women who have finished breast cancer treatment and have no signs of active disease. It may help improve how you cope, stay informed, and manage life after treatment.
PamplonaAges 18–99 - NCT06242470RecruitingPhase 1
Study of MGC026 for advanced solid tumors
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
Los Angeles, CaliforniaAges 18 years+ - NCT06245889RecruitingPhase 2
PET-Guided Therapy for Triple-Negative Breast Cancer
This trial tests whether a special PET scan can help guide the best combination of chemotherapy and immunotherapy before surgery for patients with triple-negative breast cancer. It aims to personalize treatment and improve outcomes.
Baltimore, MarylandAges 18 years+
Hear when a new Breast trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast?
- Yes. Clin2 currently lists 2,627 recruiting breast studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.